用免疫蛋白质组学鉴定克罗恩病的新生物标记物
|
By LabMedica International staff writers Posted on 06 Apr 2017 |

图片:一项研究的目的是开发更好的克罗恩病血液检验,也许有助于诊断、理解和治疗克罗恩病(图片蒙亚利桑那州立大学生物设计研究所惠赐)。
一项致力于开发更好的克罗恩病血液检验的研究利用一种新的筛查方法成功发现了几种能用作诊断标记物的抗体。
这项研究的基础是克罗恩病与针对自身蛋白质的免疫应答之间的联系,研究负责人是美国亚利桑那州立大学生物设计研究所的两位科学家Josh LaBaer和Ji Qiu,还有梅奥诊所亚利桑那州分部的肠胃病学家Shabana Pasha和Jonathan Leighton。
目前,诊断可能非常困难,需要动用昂贵的MRI、创伤性的活检或者记录症状。克罗恩病的病因仍是个谜,但是免疫系统被某种方式触发去攻击肠。知道这一点后,LaBaer教授和Qiu教授提出了一种新的蛋白质组学方法,广泛筛查血液中的免疫系统蛋白质,以发现早期预警的标记物。
Qiu教授说:“越来越多的证据表明克罗恩病的免疫应答也许是肠道微生物变化或接触有害毒素的结果,毒素导致体内产生很多针对微生物蛋白质和人类蛋白质的抗体,这是克罗恩病特有的表象。发现了许多可能的血液生物标记物,但目前临床实践尚未广泛采用商用的血检产品,因为它们无法准确诊断克罗恩病。”
科研人员开发了一种称为核酸可编程蛋白质阵列(NAPPA)的方法,避免通过耗时而昂贵的标准蛋白质提纯法制作蛋白质阵列,而是在检验时用涂片上更稳定的DNA制作新鲜蛋白质。他们用这一方法探测48名患者和48名健康对照者的血清(取自美国明尼苏达州罗彻斯特市梅奥诊所和梅奥诊所亚利桑那州分部的生物库),比对阵列上的蛋白质——从LaBaer教授的人类基因集合库收集的1906种独特蛋白质。
将患者体内的几种灵敏度超过15%的自身抗体定为候选标记物,然后用一组独立的患者和对照者确证。用最佳的几种编成一组生物标记物,使新检验方法的准确度达到最优。Qiu教授说:“生物标记物研究可能受灵敏度和特异性问题的困扰。我们不得不确保它们达到要求的分类性能,能区分患者与健康对照者以及其他肠病患者。”
最有希望的候选生物标记物是针对细菌鞭毛蛋白的抗体,它在阵列上呈现出最强的反应性和最多的数量,在保证95%特异性的情况下达到46%的灵敏度。一种新颖的生物标记物是抗SNRPB(小核核糖核蛋白相关蛋白B与B')的抗体,它在蛋白质合成中起一定作用。SNRPB还与狼疮患者有关,被称为“史密斯抗原”。
检测这些自身抗体对于我们理解克罗恩病意味着什么?LaBaer教授说:“一种可能性是这些抗体反映了肠内免疫应答失调。另一种可能性是它们可能扮演着病原体的角色。但迄今为止我们仍未发现足够多的这类抗体来理解它们的功用。”研究用到的约2,000种人类蛋白质只占集合库中3万多种独特的人类与微生物蛋白质的一小部分。他们将进一步研究自身抗体和微生物组学研究中的针对克罗恩病相关微生物的抗体。
LaBaer教授说:“没有一种生物标记物有预测能力并达到临床要求。只有一组各自经过确证的生物标记物才能在临床上达到最佳性能。但这种检测克罗恩病的免疫蛋白质组学方法的潜力令我们激动万分,我们将致力于发现更多生物标记物。”
Wang H等人将该研究的论文发表于2017年2月14日的《克罗恩病与结肠炎杂志》(Journal of Crohn’s and Colitis)。
山间医疗系统
这项研究的基础是克罗恩病与针对自身蛋白质的免疫应答之间的联系,研究负责人是美国亚利桑那州立大学生物设计研究所的两位科学家Josh LaBaer和Ji Qiu,还有梅奥诊所亚利桑那州分部的肠胃病学家Shabana Pasha和Jonathan Leighton。
目前,诊断可能非常困难,需要动用昂贵的MRI、创伤性的活检或者记录症状。克罗恩病的病因仍是个谜,但是免疫系统被某种方式触发去攻击肠。知道这一点后,LaBaer教授和Qiu教授提出了一种新的蛋白质组学方法,广泛筛查血液中的免疫系统蛋白质,以发现早期预警的标记物。
Qiu教授说:“越来越多的证据表明克罗恩病的免疫应答也许是肠道微生物变化或接触有害毒素的结果,毒素导致体内产生很多针对微生物蛋白质和人类蛋白质的抗体,这是克罗恩病特有的表象。发现了许多可能的血液生物标记物,但目前临床实践尚未广泛采用商用的血检产品,因为它们无法准确诊断克罗恩病。”
科研人员开发了一种称为核酸可编程蛋白质阵列(NAPPA)的方法,避免通过耗时而昂贵的标准蛋白质提纯法制作蛋白质阵列,而是在检验时用涂片上更稳定的DNA制作新鲜蛋白质。他们用这一方法探测48名患者和48名健康对照者的血清(取自美国明尼苏达州罗彻斯特市梅奥诊所和梅奥诊所亚利桑那州分部的生物库),比对阵列上的蛋白质——从LaBaer教授的人类基因集合库收集的1906种独特蛋白质。
将患者体内的几种灵敏度超过15%的自身抗体定为候选标记物,然后用一组独立的患者和对照者确证。用最佳的几种编成一组生物标记物,使新检验方法的准确度达到最优。Qiu教授说:“生物标记物研究可能受灵敏度和特异性问题的困扰。我们不得不确保它们达到要求的分类性能,能区分患者与健康对照者以及其他肠病患者。”
最有希望的候选生物标记物是针对细菌鞭毛蛋白的抗体,它在阵列上呈现出最强的反应性和最多的数量,在保证95%特异性的情况下达到46%的灵敏度。一种新颖的生物标记物是抗SNRPB(小核核糖核蛋白相关蛋白B与B')的抗体,它在蛋白质合成中起一定作用。SNRPB还与狼疮患者有关,被称为“史密斯抗原”。
检测这些自身抗体对于我们理解克罗恩病意味着什么?LaBaer教授说:“一种可能性是这些抗体反映了肠内免疫应答失调。另一种可能性是它们可能扮演着病原体的角色。但迄今为止我们仍未发现足够多的这类抗体来理解它们的功用。”研究用到的约2,000种人类蛋白质只占集合库中3万多种独特的人类与微生物蛋白质的一小部分。他们将进一步研究自身抗体和微生物组学研究中的针对克罗恩病相关微生物的抗体。
LaBaer教授说:“没有一种生物标记物有预测能力并达到临床要求。只有一组各自经过确证的生物标记物才能在临床上达到最佳性能。但这种检测克罗恩病的免疫蛋白质组学方法的潜力令我们激动万分,我们将致力于发现更多生物标记物。”
Wang H等人将该研究的论文发表于2017年2月14日的《克罗恩病与结肠炎杂志》(Journal of Crohn’s and Colitis)。
山间医疗系统
Latest 免疫学 News
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







